Latest information on long-term efficacy and safety on the Zilver PTX programme

Thomas Zeller, MD
Universitäts-Herzzentrum
Freiburg – Bad Krozingen, Germany
Thomas Zeller, MD

For the 12 months preceding this presentation, I disclose the following types of financial relationships:

- **Honoraria received from**: Abbott Vascular, Veryan, Biotronik, Boston Scientific Corp., Cook Medical, Gore & Associates, Medtronic, Philips-Spectranetics, TriReme, Veryan, Shockwave, Biotronik, B. Braun

- **Consulted for**: Boston Scientific Corp., Cook Medical, Gore & Associates, Medtronic, Spectranetics, Veryan, Intact Vascular, Veryan

- **Common stock**: QT Medical
Zilver PTX Stent Overview

Coating
Low dose, amorphous coating with no polymer or excipient

Local Drug Delivery
Short-term drug delivery, no long-term paclitaxel exposure, only BMS remains

Long-term data
Only peripheral DES with long-term safety data
TRIAL DESIGN

Primary Randomization

- Zilver PTX Group
- PTA / BMS Group

Zilver PTX Randomized Trial

PTA
n=237

Zilver PTX
n=242
Randomization

- RCTs are not designed to ensure balance across numerous baseline risk factors
- Randomization was stratified only by lesion length
  - Stratification by lesion length does not ensure balance across multiple patient comorbidities and demographics
Mortality Analysis

- 5-year vital status for 94% of patients
- DES patients included in PTA group
- Not significant
- Difference may be due to imbalance of risk factors

<table>
<thead>
<tr>
<th>Survival</th>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>100%</td>
<td>0</td>
</tr>
<tr>
<td>90%</td>
<td>1</td>
</tr>
<tr>
<td>80%</td>
<td>2</td>
</tr>
<tr>
<td>70%</td>
<td>3</td>
</tr>
<tr>
<td>60%</td>
<td>4</td>
</tr>
<tr>
<td>50%</td>
<td>5</td>
</tr>
<tr>
<td>40%</td>
<td></td>
</tr>
<tr>
<td>30%</td>
<td></td>
</tr>
<tr>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>10%</td>
<td></td>
</tr>
<tr>
<td>0%</td>
<td></td>
</tr>
</tbody>
</table>

PTA Primary Randomization
- n=237
- Died=34
- KM=15.2%

Zilver PTX Primary Randomization
- n=242
- Died=50
- KM=21.7%

p=0.08
Baseline Mortality Risk Factors

- Risk factors common in PAD patients may collectively contribute to overall patient prognosis
- Imbalance of risk factors, despite randomization
Baseline Patient Risk Factors for Mortality

- Combinations of risk factors more prevalent in Zilver PTX primary randomization group (p<0.01)

<table>
<thead>
<tr>
<th>Risk Factors</th>
<th>PTA Primary Randomization</th>
<th>Zilver PTX Primary Randomization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-3</td>
<td>18%</td>
<td>7%</td>
</tr>
<tr>
<td>4-6</td>
<td>50%</td>
<td>56%</td>
</tr>
<tr>
<td>7+</td>
<td>33%</td>
<td>37%</td>
</tr>
</tbody>
</table>
Mortality rate decreases with fewer risk factors

- DES 1-3 Risk Factors
- PTA/BMS 1-3 Risk Factors
- DES 4-6 Risk Factors
- PTA/BMS 4-6 Risk Factors
- DES 7+ Risk Factors
- PTA/BMS 7+ Risk Factors
TRIAL DESIGN

Secondary Randomization

Zilver PTX Group
PTA / BMS Group

PTA
n=237

Optimal PTA
n=118

Suboptimal PTA

BMS
n=56

Zilver PTX
n=63
TRIAL DESIGN

Early Crossover

Primary Randomization

PTA
n=237

Suboptimal PTA

Optimal PTA
n=118

Zilver PTX
n=242

PTA / BMS Group

Zilver PTX Group

Secondary Randomization

BMS
n=56\(^1\)

Zilver PTX
n=63

Protocol:
Reintervention
in the first year

Median: 183 days

Zilver PTX
n=30

\(^1\) One BMS patient received Zilver PTX during reintervention within the first year.
Treatment Results

Primary Randomization
- N=242
- N=237

Primary + Secondary Randomization
- N=305
- N=174

Actual Treatment = Primary + Secondary + Crossover
- N=336
- N=143

40% of patients initially randomized to PTA were actually treated with Zilver PTX
Mortality Analysis

- All patients analyzed by actual treatment
- No mortality signal

<table>
<thead>
<tr>
<th>PTA/BMS</th>
<th>Zilver PTX</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=143</td>
<td>n=336</td>
</tr>
<tr>
<td>Died=23</td>
<td>Died=61</td>
</tr>
<tr>
<td>KM=17.1%</td>
<td>KM=19.1%</td>
</tr>
</tbody>
</table>

\[ p=0.60 \]
ACTUAL TREATMENT

Risk Factor Mortality Analysis

- Mortality rate decreases with fewer risk factors
- No mortality signal for actual treatment

<table>
<thead>
<tr>
<th>Risk Factor Category</th>
<th>Graph Line</th>
</tr>
</thead>
<tbody>
<tr>
<td>DES 1-3 Risk Factors</td>
<td>Red</td>
</tr>
<tr>
<td>PTA/BMS 1-3 Risk Factors</td>
<td>Red dashes</td>
</tr>
<tr>
<td>DES 4-6 Risk Factors</td>
<td>Green</td>
</tr>
<tr>
<td>PTA/BMS 4-6 Risk Factors</td>
<td>Green dashes</td>
</tr>
<tr>
<td>DES 7+ Risk Factors</td>
<td>Blue</td>
</tr>
<tr>
<td>PTA/BMS 7+ Risk Factors</td>
<td>Blue dashes</td>
</tr>
</tbody>
</table>
Conclusions and Next Steps

• Vital status through 5 years for 94% of patients
• Intent-to-treat:
  - No significant difference in mortality;
  - Imbalance in risk factors (p<0.01), despite randomization
• Actual treatment:
  - 40% of patients in PTA primary randomization group treated with Zilver PTX
• No mortality signal
The patient-level data used for the analyses presented here is available on the following website:

https://www.cookmedical.com/peripheral-intervention/paclitaxel/
TLR teaser slide

- Introduce TLR to be discussed in lunch symposium

Paclitaxel and your practice: Global perspectives
12:30-13:25
Room 1, Main Arena 1
Latest information on long-term efficacy and safety on the Zilver PTX programme

Thomas Zeller, MD
Universitäts-Herzzentrum
Freiburg – Bad Krozingen, Germany